Quality Assessment: Outstanding Financial Performance
Asarfi Hospital has demonstrated exceptional financial strength in the recent quarter ending December 2025. The company reported net sales of ₹46.10 crores, marking its highest quarterly sales to date. Profitability metrics have also surged, with PBDIT reaching ₹10.11 crores and net profit growing by an impressive 29.05% compared to the previous quarter. This marks the third consecutive quarter of positive results, underscoring consistent operational excellence.
Return on Capital Employed (ROCE) for the half-year period stands at a robust 18.55%, signalling efficient capital utilisation. The company’s debt servicing capability remains strong, with a low Debt to EBITDA ratio of 1.20 times, reflecting prudent financial management and limited leverage risk. These factors contribute to a high-quality rating, reinforcing investor confidence in Asarfi Hospital’s fundamentals.
Valuation: Very Attractive Amid Growth
From a valuation perspective, Asarfi Hospital presents a compelling case for investors. The stock currently trades at ₹163.00, up 3.30% on the day, with a 52-week high of ₹221.00 and a low of ₹72.90. The company’s Enterprise Value to Capital Employed ratio is a modest 2.7, indicating undervaluation relative to its capital base and earnings potential.
Moreover, the Price/Earnings to Growth (PEG) ratio is an exceptionally low 0.1, signalling that the stock’s price growth has not yet fully reflected its earnings acceleration. Over the past year, the stock has delivered a remarkable 70.22% return, significantly outperforming the broader market benchmark BSE500’s 14.43% return. This market-beating performance, combined with strong profit growth of 161% over the same period, supports the upgraded Buy rating.
This week's revealed pick, a Large Cap from Public Banks with TARGET PRICE, is already showing movement! Get the complete analysis before it's too late.
- - Target price included
- - Early movement detected
- - Complete analysis ready
Financial Trend: Sustained Growth with Some Long-Term Caution
Asarfi Hospital’s financial trend remains largely positive, driven by strong quarterly results and consistent profit growth. The company’s net profit has surged by 29.05% in the latest quarter, while operating profit has grown at an annualised rate of 14.76% over the past five years. Although this long-term growth rate is moderate, the recent acceleration in profitability and sales volume is encouraging.
Return on Capital Employed (ROCE) for the half-year period is at 18.55%, with a trailing twelve-month ROCE of 14.5%, indicating efficient use of capital and improving operational leverage. The company’s ability to maintain a low Debt to EBITDA ratio of 1.20 times further supports a stable financial trend, reducing risk from excessive leverage.
However, investors should note that the operating profit growth over the last five years, while positive, is not exceptionally high, suggesting some caution regarding the sustainability of rapid expansion in the longer term.
Technical Analysis: Shift to Mildly Bullish Momentum
The technical outlook for Asarfi Hospital has improved notably, prompting a revision in the technical grade from sideways to mildly bullish. Daily moving averages have turned mildly bullish, reflecting recent upward price momentum. The weekly KST (Know Sure Thing) indicator is bullish, signalling positive momentum in the near term.
However, some mixed signals remain. The weekly MACD is mildly bearish, and Bollinger Bands on the weekly chart also indicate mild bearishness, while the monthly Bollinger Bands are bullish. The Dow Theory readings are mildly bearish on both weekly and monthly timeframes, suggesting some caution in the broader trend.
Overall, the technical indicators point to a cautiously optimistic outlook, with the stock showing signs of upward momentum but still facing some resistance and volatility. This nuanced technical picture supports the upgrade to a Buy rating, reflecting improved but not yet unequivocal bullishness.
Comparative Market Performance
Asarfi Hospital’s stock has outperformed the Sensex and broader market indices over the past year. While the stock returned 70.22% in the last 12 months, the Sensex gained only 9.62% and the BSE500 index 14.43%. This outperformance highlights the company’s strong market positioning and investor appeal.
Shorter-term returns have been mixed, with the stock declining 1.03% over the past week and 6.86% over the past month, compared to Sensex declines of 3.67% and 1.75% respectively. Year-to-date, the stock is down 13.34%, underperforming the Sensex’s 5.85% decline. These fluctuations reflect broader market volatility and sector-specific dynamics but do not detract from the company’s strong long-term growth trajectory.
Curious about Asarfi Hospital Ltd from Hospital? Get the complete picture with our detailed research report covering fundamentals, technicals, peer analysis, and everything you need to decide!
- - Detailed research coverage
- - Technical + fundamental view
- - Decision-ready insights
Shareholding and Industry Context
The majority shareholding in Asarfi Hospital remains with promoters, ensuring stable ownership and aligned interests with long-term investors. Operating within the Hospital & Healthcare Services sector, the company benefits from structural growth drivers such as rising healthcare demand and increasing medical infrastructure investments.
Its market capitalisation grade stands at 4, reflecting a mid-sized company with growth potential. The Mojo Score of 78.0 and upgraded Mojo Grade to Buy from Hold further validate the positive outlook based on a balanced assessment of quality, valuation, financial trends, and technicals.
Risks and Considerations
Despite the positive upgrade, investors should remain mindful of certain risks. The company’s operating profit growth over the last five years, while steady, is not exceptionally high at 14.76% annually, which may limit long-term upside. Additionally, some technical indicators remain mildly bearish, suggesting potential volatility ahead.
Market conditions and sector-specific challenges, such as regulatory changes or competitive pressures, could also impact performance. Nonetheless, the current combination of strong quarterly results, attractive valuation, and improving technical momentum supports a constructive investment thesis.
Conclusion
Asarfi Hospital Ltd’s upgrade to a Buy rating reflects a comprehensive improvement across four key parameters. The company’s outstanding recent financial performance, very attractive valuation metrics, sustained positive financial trends, and a shift to mildly bullish technical indicators collectively underpin this positive reassessment. While some caution remains warranted due to moderate long-term growth rates and mixed technical signals, the overall outlook is favourable for investors seeking exposure to the hospital sector’s growth potential.
With a market-beating 70.22% return over the past year and strong fundamentals, Asarfi Hospital is well positioned to deliver value in the medium term. Investors should monitor quarterly results and technical developments closely to capitalise on emerging opportunities.
Only Rs. 9,999 - Get MojoOne for 1 Year + 3 Months FREE (60% Off) Start Today
